A handful of almonds a day might fill a nutrition gap in GLP-1 users
NCT ID NCT07796204
First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time
Summary
This 8-week pilot trial tests whether eating at least 56 grams of almonds daily can raise blood levels of vitamin E and improve overall diet quality in adults taking GLP-1 medications like semaglutide or tirzepatide for obesity or type 2 diabetes. Participants are split into two groups: one adds almonds to their usual diet, the other follows their usual diet without almonds. Researchers measure vitamin E in the blood and use a phone app to track diet quality. The goal is to see if a simple food addition can help fill nutritional gaps that may come with GLP-1 treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Almonds (provided as a dietary supplement, up to 84 grams per day, with coaching to eat at least 56 grams daily)
- What this could lead to
- If almonds help, they could offer a simple, food-based way to improve nutrition and vitamin E levels for people taking GLP-1 medications for weight or diabetes management.
- What could go wrong
- This is a small pilot trial, so results may not apply broadly. Almonds add calories, which could affect weight loss, and the study does not provide the GLP-1 medication itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 76 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18-70 years * BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication * Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study) * HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria * Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator * Enroll and complete baseline assessments prior to starting pharmacotherapy * Able and willing to adhere to all study-related procedures Exclusion Criteria: * Pregnancy or breastfeeding * Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels * Previous use of a glucagon-like peptide-1 medication in the last 3 months * Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication * Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure * History of bariatric surgery * Allergic to almonds * Active malignancy, excluding some skin cancers, or undergoing chemotherapy/radiotherapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70806, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The acute effects of an endurance exercise bout the gut microbiome and gut-derived metabolome in Women's distinct fitness and body mass indexes
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- The feasibility of electrical impedance tomography to guide non-invasive respiratory interventions in chronic respiratory disease
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- Can a new injection help tackle obesity? a trial puts it to the test